Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Chelsea Therapeutics International, Ltd. ("Chelsea Therapeutics" or the "Company") (NasdaqCM: CHTP), concerning whether the company and certain of its officers and directors have violated federal securities laws.

On February 13, 2012, Shares of Chelsea Therapeutics plunged 36% to $3.21 in early trading Monday after the biotechnology company said health regulators had raised questions about the size and duration of studies of its hypotension drug Northera. The U.S. Food and Drug Administration is slated to decide on whether to approve Nothera by March 28. The official FDA panel will convene Feb. 23 to review the Northera data.

Three deaths were noted in a company trial of Northera "as being possibly related to the study drug." The drug aims to treat neurogenic orthostatic hypotension, or NOH, a condition common in patients with Parkinson's disease and related disorders. NOH is often characterized by dizziness, fatigue and fainting.

If you are aware of any facts relating to this investigation, or purchased shares of Chelsea Therapeutics, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
eitan@bgandg.com